Glioblastoma overall survival

• Optimizing GBM organoid construction with hydrogel-based models: GelMA-HAMA scaffold supports GBM organoids with clonal growth for drug screening
• Comprehensive multi-omics approach reveals critical genes and immunometabolic networks in glioblastoma
• Hybrid Therapy for Newly Diagnosed and Recurrent Glioblastoma: Staged Procedure Integrating Open Surgical Resection With Laser Interstitial Thermal Therapy
• Patient-Derived Glioblastoma Explants Empower Rapid and Personalized Drug Assessment: Harnessing the Potential of 3D Perfusion Bioreactors in Glioblastoma Drug Discovery
• Modeling Glioma Stem Cell-Mediated Tumorigenesis Using Zebrafish Patient-Derived Xenograft Systems
• An In Vivo Model of Recurrent Glioblastoma
• Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers
• Loss of PDE10A is associated with metastasis of colon adenocarcinoma

see also Glioblastoma prognosis.

Overall survival (OS) in glioblastoma patients varies depending on factors such as age, performance status, extent of surgical resection, and molecular characteristics of the tumor.

Standard of Care: For patients treated with maximal safe surgical resection, followed by radiation therapy with concurrent and adjuvant temozolomide (Stupp protocol), the median OS is approximately 14–18 months. Without Treatment: Median survival drops to approximately 3–6 months.

2-Year Survival: Around 25–30% of patients.

5-Year Survival: Rare, seen in about 5% of patients, often linked to favorable molecular features like IDH mutations. Not really glioblastoma.

IDH Mutation:

GBM with IDH mutation (IDH-mutant glioblastoma) has a better prognosis with longer OS compared to IDH-wildtype GBM.

MGMT Promoter Methylation:

MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation predicts better response to temozolomide and is associated with longer OS.

TERT Promoter Mutations:

Common in GBM but generally associated with poorer prognosis unless paired with other favorable markers.

1p/19q Co-deletion:

Rare in GBM and more characteristic of oligodendrogliomas, with a better prognosis in these cases.

Emerging Treatments and Survival Impact

Tumor Treating Fields (TTF): Can extend median survival by a few months when used in conjunction with standard therapy.

Immunotherapy: Limited success so far, but ongoing trials may change outcomes.

Targeted Therapy: Exploring pathways like EGFR, VEGF, and others has shown mixed results.

Clinical Trials: Participation in trials offers access to novel treatments that might improve outcomes.

While progress has been made, GBM remains one of the most challenging cancers to treat, with a strong focus on extending quality of life alongside survival.

In glioblastoma, progression-free survival (PFS) and overall survival (OS) are strongly correlated, indicating that PFS may be an appropriate surrogate for OS. Compared with OS, PFS offers earlier assessment and higher statistical power at the time of analysis ¹⁾.

Increasing the extent of resection (EOR) of Glioblastoma is associated with prolonged survival ²⁾

Also, adjuvant radiochemotherapy showed higher survival rates in patients with complete resection (EOR ≥ 90%), compared with partial resection (EOR < 90%) ³⁾.

Glioblastoma IDH Mutant is associated with better outcome and increased overall survival ⁴⁾.

Overall estimates of survival among patients with glioblastoma have at least doubled since 2005 to 18% at 2 years and 11% at 3 years. This may reflect treatment response to modern therapeutic approaches. However, longer-term survival remains poor and there appears to be a lack of improvement in 5-year survival ⁵⁾.

Magnetic resonance perfusion imaging parameter obtained on 3-Tesla and the Ki-67 labeling index predict the overall survival of glioblastoma ⁶⁾.

MR image derived texture features, tumor shape and volumetric features, and patient age were obtained for 163 patients. OS group prediction was performed for both 2-class (short and long) and 3-class (short, medium and long) survival groups. Support vector machine classification based recursive feature elimination method was used to perform feature selection. The performance of the classification model was assessed using 5-fold cross-validation. The 2-class and 3-class OS group prediction accuracy obtained were 98.7% and 88.95% respectively. The shape features used in this work have been evaluated for OS prediction of Glioblastoma patients for the first time. The feature selection and prediction scheme implemented in this study yielded high accuracy for both 2-class and 3-class OS group predictions. This study was performed using routinely acquired MR images for Glioblastoma patients, thus making the translation of this work into a clinical setup convenient ⁷⁾.

A retrospective study included patients diagnosed with glioblastoma from the multicenter BraTioUS database. A single 2D iUS slice, showing the largest tumor diameter, was selected for each patient. Radiomic features were extracted and subjected to feature selection, and clinical data were collected. Using a fivefold cross-validation strategy, Cox proportional hazards models were built using radiomic features alone, clinical data alone, and their combination. Model performance was assessed via the concordance index (C-index).

A total of 114 patients met the inclusion criteria, with a mean age of 56.88 years, a median OS of 382 days, and a median preoperative tumor volume of 32.69 cm3. Complete tumor resection was achieved in 51.8% of the patients. In the testing cohort, the combined model achieved a mean C-index of 0.87 (95% CI: 0.76-0.98), outperforming the radiomic model (C-index: 0.72, 95% CI: 0.57-0.86) and the clinical model (C-index: 0.73, 95% CI: 0.60-0.87).

Intraoperative ultrasound relies on acoustic properties for tissue characterization, capturing unique features of glioblastomas. This study demonstrated that radiomic features derived from this imaging modality have the potential to support the development of survival models ⁸⁾.

This study makes a significant contribution to the emerging field of intraoperative radiomics by demonstrating the prognostic potential of iUS features in glioblastoma patients. However, its limitations, particularly the small sample size, retrospective design, and lack of external validation, necessitate further research to confirm the findings and establish their clinical utility. By addressing these gaps, future studies can ensure that such models become valuable tools for optimizing treatment strategies in glioblastoma management.